Sutro Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview

Sutro Biopharma

09/08/2025 01:39

Sutro Biopharma Inc STRO.OQ STRO.O is expected to  show a rise in quarterly revenue when it reports  results  for the period ending September 30 2025

The South San Francisco California-based  company is expected to report a 44.5% increase in revenue to $12.31 million from $8.52 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 16.9% in the last three months. ​

Wall Street's median 12-month price target for Sutro Biopharma Inc is $2.00, about 59.9% above its last closing price of $0.80

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.41
-0.40
-0.14
Beat
65.2
Mar. 31 2025
-0.70
-0.71
-0.91
Missed
-28.6
Dec. 31 2024
-0.78
-0.83
-0.89
Missed
-7.1​
Sep. 30 2024
-0.73
-0.73
-0.59
Beat
19.7
​​Jun. 30 2024
-0.76
-0.79
-0.59
Beat
25.5
Mar. 31 2024
-0.88
-0.92
-0.95
Missed
-3​
Dec. 31 2023
-0.82
0.52
Beat
163.2
Sep. 30 2023
-0.74
-0.74
-0.81
Missed
-10.1

This summary was machine generated August 9 at 00:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)